<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03247673</url>
  </required_header>
  <id_info>
    <org_study_id>CT-P16 1.1</org_study_id>
    <nct_id>NCT03247673</nct_id>
  </id_info>
  <brief_title>To Demonstrate Similarity of Pharmacokinetics and Evaluate Safety of CT-P16, EU-Approved Avastin and US-licensed Avastin</brief_title>
  <official_title>A Randomized, Double-blind, Three-arm, Parallel Group, Single-dose Study to Compare the Pharmacokinetics and Safety of Three Formulations of Bevacizumab (CT-P16, EU-approved Avastin and US-licensed Avastin) in Healthy Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Celltrion</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Celltrion</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a Phase 1 Randomized, Double-blind, Three-arm, Parallel Group, Single-dose
      Study to compare the PK, safety and immunogenicity of the proposed biosimilar test product
      CT-P16 with EU-approved Avastin and US-licensed Avastin after a single IV infusion of 5mg/kg
      of each product to healthy male subjects
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 7, 2017</start_date>
  <completion_date type="Anticipated">April 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetics: Area under the concentration-time curve from time zero to infinity</measure>
    <time_frame>Daily to Biweekly up to 15 weeks</time_frame>
    <description>To demonstrate the similarity of the pharmacokinetics (PK) in terms of area under the concentration-time curve from zero to infinity</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Additional Pharmacokinetics (Time to Cmax)</measure>
    <time_frame>Daily to Biweekly up to 15 weeks</time_frame>
    <description>To assess the additional PK of study drugs (Time to Cmax)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety(Vital signs, immunogenicity)</measure>
    <time_frame>Daily to Biweekly up to 15 weeks</time_frame>
    <description>To evaluate the safety and immunogenicity of study drugs in healthy male subjects(Vital signs: blood pressure(mmHg), heart rate(beats/min), body temperature(℃), respiratory rate(breaths/min), Immunogenicity: serum measures in a validated immunoassay)</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">141</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>CT-P16</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CT-P16 will be administrated once in IV infusion of 5mg/KG to healthy male subjects</description>
  </arm_group>
  <arm_group>
    <arm_group_label>EU-approved Avastin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>EU-approved Avastin will be administrated once in IV infusion of 5mg/KG to healthy male subjects</description>
  </arm_group>
  <arm_group>
    <arm_group_label>US-licensed Avastin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>US-licensed Avastin will be administrated once in IV infusion of 5mg/KG to healthy male subjects</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CT-P16</intervention_name>
    <description>CT-P16 is a biosimilar product for Avastin</description>
    <arm_group_label>CT-P16</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>EU-approved Avastin</intervention_name>
    <description>EU-approved Avastin</description>
    <arm_group_label>EU-approved Avastin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>US-licensed Avastin</intervention_name>
    <description>EU-approved Avastin</description>
    <arm_group_label>US-licensed Avastin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy male subjects between the ages of 19 and 55 years, both inclusive

          -  Body Mass Index (BMI) between 18.0 and 29.9 kg/m2 (both inclusive) and a body weight ≥
             50 kg

        Exclusion Criteria:

          -  Subject is a female.

          -  Clinically significant allergic reactions, hypersensitivity

          -  A disease classed as significant by the Investigator

          -  Non-healing wound, ulcer, bone fracture, a major surgical procedure, significant
             traumatic injury

          -  Any malignancy

          -  Undergone treatment with an investigational drug or participated in another clinical
             trial

          -  Plans to father a child or donates sperms
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sung Young Lee</last_name>
    <role>Study Director</role>
    <affiliation>Celltrion</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sul Lee</last_name>
    <phone>82328506526</phone>
    <email>Sul.Lee@celltrion.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ji Suk Yoo</last_name>
    <phone>82328506580</phone>
    <email>JiSuk.Yoo@celltrion.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Inje University Busan Paik Hospital</name>
      <address>
        <city>Busan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jae Gook Shin</last_name>
      <phone>82518906709</phone>
      <email>phshinjg@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Jae Gook Shin, Professor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Inha University Hospital</name>
      <address>
        <city>Incheon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sang Heon Cho</last_name>
      <phone>82328901122</phone>
      <email>shcho123@inha.ac.kr</email>
    </contact>
    <investigator>
      <last_name>Sang Heon Cho, Professor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Seoul St.Mary's hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Seung Hoon Han</last_name>
      <phone>82222587326</phone>
      <email>waystolove@catholic.ac.kr</email>
    </contact>
    <investigator>
      <last_name>Seung Hoon Han, Professor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <link>
    <url>http://www.celltrion.com</url>
    <description>Celltrion, Inc. homepage</description>
  </link>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 3, 2017</study_first_submitted>
  <study_first_submitted_qc>August 10, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">August 14, 2017</study_first_posted>
  <last_update_submitted>August 10, 2017</last_update_submitted>
  <last_update_submitted_qc>August 10, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 14, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>safety</keyword>
  <keyword>Pharmacokinetics</keyword>
  <keyword>Immunogenicity</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

